Globitair

Stock market

All-or-Nothing Biotech Bets Dented by Rising Treasury Yields

Bloomberg Markets

Investors are beginning to turn cautious on biotechnology stocks as a rapid rise in Treasury yields dents the appeal for shares of companies that are often viewed as risky all-or-nothing bets on breakthrough medical treatments.

Read the full story at Bloomberg MarketsOpen in the live monitor

Related discussion groups

No group discusses this yet. Start a discussion group and attach this story.

More on Stock market